Home » NeoPharm Gets FDA Orphan Drug Designation for IPF Treatment
NeoPharm Gets FDA Orphan Drug Designation for IPF Treatment
NeoPharm announced Monday that the Office of Orphan Products Development of the FDA has granted orphan-drug designation for IL13-PE38QQR for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
MarketWatch
MarketWatch
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May